New Delhi, July 20: India’s efforts to strengthen dengue prevention received a major boost with regulatory approval for Qdenga, described as the country’s first approved dengue vaccine.
The vaccine has received clearance for use among individuals aged 4 to 60 years and can be administered without requiring prior screening to determine whether a person has previously been infected with dengue. The development introduces a new preventive option against a mosquito borne disease that continues to pose a significant public health challenge in India.
Dengue is transmitted primarily by infected Aedes mosquitoes and can cause symptoms ranging from high fever, severe headache and muscle pain to potentially life threatening complications. Prevention has traditionally relied heavily on mosquito control measures, eliminating breeding sites and protecting people from mosquito bites.
The approval of a vaccine adds another layer to those preventive efforts. Health experts have emphasised that vaccination does not eliminate the need for vector-control measures, particularly in areas where dengue transmission remains common.
The vaccine’s approval also comes as Indian states continue to strengthen surveillance and preparedness for seasonal infectious diseases. Health authorities have been monitoring dengue trends while urging communities to reduce stagnant water around homes and workplaces, where mosquitoes can breed.
The broader significance of the approval lies in expanding India’s disease-prevention toolkit. A vaccine-based approach could complement existing public-health strategies and potentially reduce the burden of dengue-related illness and hospitalisation.
The development is particularly relevant for children and adults living in dengue-prone regions, where repeated exposure to the virus remains a concern.
With regulatory clearance now in place, the next phase will involve decisions surrounding availability, deployment and public awareness. Health authorities will also need to ensure that vaccination strategies are supported by continued disease surveillance and mosquito control programmes.
